MultiOmic Health Partners with Serbia's BIO4 Campus to Develop AI-Driven Precision Medicine for Cardio-Renal-Metabolic Diseases
核心洞察
MultiOmic Health Limited (搜索) and BIO4 Campus (搜索) signed a memorandum of understanding to collaborate on precision medicine research focused on cardio-renal-metabolic diseases (搜索) using AI and multi-omics approaches.
The partnership will develop AI-enabled tools to stratify patient endotypes at earlier disease stages and identify patient-specific drug targets through integrative analysis of genetics, epigenetics, transcriptomics, proteomics and metabolomics.
The collaboration aims to create AI-based Software as Medical Device and In Vitro Diagnostic products to optimize patient care pathways and enable more personalized treatment approaches.
MultiOmic Health Limited (搜索), an artificial intelligence-enabled precision medicine biotechnology company, has entered into a strategic partnership with BIO4 Campus (搜索), Serbia's flagship biotechnology and life sciences hub, to advance precision medicine solutions for cardio-renal-metabolic diseases (搜索). The memorandum of understanding, announced on September 4, 2025, establishes a collaborative framework to explore opportunities in biomedicine, biotechnology and bioinformatics with a strong emphasis on AI applications.
Multi-Omics Approach to Patient Stratification
The collaboration will initially focus on cardio-renal-metabolic diseases (搜索) through integrative medical data and multi-omics approaches encompassing genetics, epigenetics, transcriptomics, proteomics and metabolomics. This comprehensive research strategy aims to discover patient endotypes with distinct clinical phenotypes and omics signatures, enabling the development of AI-enabled tools to stratify patient populations at earlier disease stages.
The partnership's research objectives include identifying and validating corresponding patient-stratified drug targets, which will facilitate a more personalized approach to patient care. These efforts represent a significant advancement in precision medicine, moving beyond traditional one-size-fits-all treatment approaches to targeted therapies based on individual patient characteristics.
Development of AI-Based Medical Devices
Insights generated from this research will enable the joint development of AI-based Software as Medical Device (SaMD) and In Vitro Diagnostic (IVD) products designed to optimize patient care pathways using existing treatment options. In parallel, MultiOmic Health will devise new superior treatment concepts, generate corresponding drug candidates and conduct clinical trials in partnership with its biopharma industry collaborators.
"By joining forces with BIO4 and its network of leading Serbian research and clinical institutions, we see a strong opportunity to advance the development of next-generation precision medicine solutions," said Robert Thong, CEO of MultiOmic Health. "This collaboration reinforces our commitment to harnessing AI, data science and experimental biology to improve patient outcomes in cardio-renal-metabolic diseases (搜索) globally."
Strategic Infrastructure and Expertise
BIO4 Campus (搜索), established by the Government of the Republic of Serbia and located in Belgrade, serves as a bioeconomy hub that brings together scientific research, higher education, and industry collaboration. The campus houses more than 1,000 PhD scientists and over 300 laboratories from 16 institutions, providing substantial research infrastructure for innovation in biomedicine, biotechnology, and bioinformatics.
"BIO4 Campus (搜索) was created to be a catalyst for Serbia's bioeconomy and an international hub for innovation," said Smiljana Krivokuća, CEO of BIO4. "We are delighted to welcome MultiOmic Health as a partner in this mission and look forward to exploring joint opportunities that combine their expertise in precision medicine with our ecosystem's strengths in biotechnology, clinical research and bioinformatics."
Focus on Cardio-Renal-Metabolic Diseases
MultiOmic Health specializes in developing precision medicine R&D programmes with AI-enabled patient-stratifier models and companion diagnostics for cardio-renal-metabolic diseases (搜索), including serious medical complications of diabetes (搜索) and hypertension (搜索). The company leverages a unique combination of deep patient clinical and multi-omics datasets, AI-enabled data science capabilities and experimental biology expertise.
The partnership represents a significant step toward fostering the growth of Serbia's bioeconomy ecosystem by identifying and developing opportunities for joint research and innovation in precision medicine, positioning both organizations at the forefront of AI-driven healthcare solutions.